Novo Nordisk (NVO) announced on Saturday that a late-stage trial for its popular weight loss therapy Ozempic in adults with ...

Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, ...

Semaglutide, the diabetes and weight loss drug that’s commonly known as Ozempic, can help patients of peripheral artery ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

Wegovy was also associated with a lower risk of hospitalization for heart failure, cardiovascular-related death, and ...

The War and Treaty singer Michael Trotter Jr. tells PEOPLE ahead of the 'Opry 100: A Live Celebration' in Nashville on March ...

4. Cardiovascular Benefits Insulin resistance is a major risk factor for cardiovascular disease. Studies have shown that Ozempic not only lowers blood sugar and insulin levels but also improves ...

Ozempic is also approved to reduce the risk of heart attack and stroke in adults with type 2 diabetes who also have heart disease. It’s not known whether Mounjaro is effective for this use.

Equinox's GLP-1 protocol is considered a framework for people taking the drugs, one that addresses workout intensity, ...

Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...